Advances and challenges in targeting IRF5, a key regulator of inflammation.
Autoimmune Diseases
/ drug therapy
DNA
/ metabolism
Dimerization
Gene Expression Regulation
/ drug effects
Genetic Therapy
Humans
Inflammation
/ drug therapy
Interferon Regulatory Factors
/ antagonists & inhibitors
Molecular Targeted Therapy
Phosphorylation
/ drug effects
Protein Binding
/ drug effects
Protein Interaction Mapping
Protein Kinase Inhibitors
/ pharmacology
Protein Processing, Post-Translational
/ drug effects
RNA Interference
RNA, Small Interfering
/ pharmacology
Signal Transduction
/ drug effects
Toll-Like Receptors
/ physiology
Transcription, Genetic
autoimmune diseases
inflammation
interferon regulatory factor 5
therapy
transcription factor
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
30
04
2018
revised:
26
07
2018
accepted:
07
09
2018
pubmed:
11
9
2018
medline:
6
5
2020
entrez:
11
9
2018
Statut:
ppublish
Résumé
Interferon regulatory factor 5 (IRF5) belongs to a family of transcription factors, originally implicated in antiviral responses and interferon production. However, studies conducted in different laboratories over the last decade have placed IRF5 as a central regulator of the inflammatory response. It has become clear that IRF5 contributes to the pathogenesis of many inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus. Given the role of IRF5 in physiology and disease, IRF5 represents a potential therapeutic target. However, despite a significant interest from the pharmaceutical industry, inhibitors that interfere with the IRF5 pathway remain elusive. Here, we review the advances made by various studies in targeting multiple steps of signalling leading to IRF5 activation with their therapeutic potential, and the possible complications of such strategies are discussed.
Identifiants
pubmed: 30199605
doi: 10.1111/febs.14654
pmc: PMC6563445
doi:
Substances chimiques
IRF5 protein, human
0
Interferon Regulatory Factors
0
Protein Kinase Inhibitors
0
RNA, Small Interfering
0
Toll-Like Receptors
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1624-1637Subventions
Organisme : Versus Arthritis
ID : 20966
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 20966
Pays : United Kingdom
Informations de copyright
© 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Immunol. 1999 Jul 15;163(2):939-46
pubmed: 10395690
EMBO J. 1999 Sep 15;18(18):5028-41
pubmed: 10487755
Gene. 1999 Sep 3;237(1):1-14
pubmed: 10524230
Annu Rev Immunol. 2001;19:623-55
pubmed: 11244049
J Biol Chem. 2001 Jun 29;276(26):23382-90
pubmed: 11303025
Mol Cell Biol. 2002 Aug;22(16):5721-40
pubmed: 12138184
J Biol Chem. 2002 Dec 13;277(50):48115-21
pubmed: 12351658
Int Immunol. 2003 Jul;15(7):807-15
pubmed: 12807819
Cancer Res. 2003 Oct 1;63(19):6424-31
pubmed: 14559832
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
Cell. 2004 Apr 16;117(2):225-37
pubmed: 15084260
J Biol Chem. 2005 Jan 28;280(4):3088-95
pubmed: 15556946
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17416-21
pubmed: 15574499
Nature. 2005 Mar 10;434(7030):243-9
pubmed: 15665823
J Biol Chem. 2005 Apr 29;280(17):17005-12
pubmed: 15695821
J Biol Chem. 2005 Jun 3;280(22):21078-90
pubmed: 15805103
Mol Cell Biol. 2005 Aug;25(15):6454-63
pubmed: 16024783
Cancer Res. 2005 Aug 15;65(16):7403-12
pubmed: 16103093
Genes Dev. 2005 Nov 15;19(22):2668-81
pubmed: 16260493
Nat Genet. 2006 May;38(5):550-5
pubmed: 16642019
J Immunol. 2006 Jun 15;176(12):7462-70
pubmed: 16751392
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3402-7
pubmed: 17360658
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6758-63
pubmed: 17412832
Hum Mol Genet. 2007 Dec 15;16(24):3008-16
pubmed: 17881657
Arthritis Res Ther. 2007;9(5):R113
pubmed: 17967186
Arthritis Rheum. 2007 Dec;56(12):3989-94
pubmed: 18050197
J Med Genet. 2008 Jun;45(6):362-9
pubmed: 18285424
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
J Biol Chem. 2008 May 23;283(21):14295-308
pubmed: 18332133
Arthritis Rheum. 2008 May;58(5):1264-74
pubmed: 18438842
Mol Cell Biol. 2008 Dec;28(24):7296-308
pubmed: 18824541
Nat Struct Mol Biol. 2008 Nov;15(11):1213-20
pubmed: 18836453
Arthritis Rheum. 2009 Jun;60(6):1661-71
pubmed: 19479877
PLoS Pathog. 2009 Jul;5(7):e1000500
pubmed: 19578435
J Exp Med. 2009 Aug 3;206(8):1661-71
pubmed: 19635858
Cell Signal. 2010 Jan;22(1):117-27
pubmed: 19786094
Nature. 2009 Nov 12;462(7270):182-8
pubmed: 19907488
Blood. 2010 Jun 3;115(22):4421-30
pubmed: 20237317
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10154-9
pubmed: 20479222
J Leukoc Biol. 2010 Dec;88(6):1171-80
pubmed: 20651301
J Biol Chem. 2010 Dec 3;285(49):38348-61
pubmed: 20817723
J Immunol. 2010 Nov 15;185(10):6003-12
pubmed: 20935208
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
PLoS Pathog. 2011 Jan 06;7(1):e1001246
pubmed: 21253574
J Immunol. 2011 Oct 15;187(8):4331-7
pubmed: 21918188
PLoS One. 2012;7(3):e33098
pubmed: 22412986
J Pharmacol Exp Ther. 2012 Jul;342(1):15-22
pubmed: 22473614
Eur J Immunol. 2012 Jun;42(6):1477-87
pubmed: 22678902
Immunobiology. 2012 Dec;217(12):1315-24
pubmed: 22995936
Adv Cancer Res. 2012;115:39-67
pubmed: 23021241
Ann Rheum Dis. 2013 Jul;72(7):1225-32
pubmed: 23041839
PLoS One. 2012;7(12):e52046
pubmed: 23251680
PLoS One. 2013;8(1):e54487
pubmed: 23349905
Curr Opin Pharmacol. 2013 Oct;13(5):791-6
pubmed: 23735579
Immunity. 2013 Jun 27;38(6):1176-86
pubmed: 23770228
N Engl J Med. 2013 Aug 29;369(9):819-29
pubmed: 23984729
Curr Opin Oncol. 2013 Nov;25(6):652-8
pubmed: 24048019
Lancet. 2014 Jan 4;383(9911):60-68
pubmed: 24094767
Nat Mater. 2013 Nov;12(11):967-77
pubmed: 24150415
Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8
pubmed: 24292632
J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66
pubmed: 24361318
Mediators Inflamm. 2013;2013:245804
pubmed: 24453413
Nat Commun. 2014 May 13;5:3771
pubmed: 24818655
PLoS One. 2014 Aug 01;9(8):e103609
pubmed: 25084355
Cell Rep. 2014 Sep 11;8(5):1308-17
pubmed: 25159141
Antiviral Res. 2014 Nov;111:53-9
pubmed: 25218783
J Interferon Cytokine Res. 2015 Feb;35(2):71-8
pubmed: 25259415
Nucleic Acids Res. 2014 Nov 10;42(20):12928-38
pubmed: 25324313
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17432-7
pubmed: 25326418
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17438-43
pubmed: 25326420
Mult Scler. 2015 Jul;21(8):984-95
pubmed: 25392335
Biotechnol Appl Biochem. 2015 Nov-Dec;62(6):738-45
pubmed: 25556956
Nat Med. 2015 Jun;21(6):610-8
pubmed: 25939064
J Immunol. 2015 Aug 1;195(3):1100-11
pubmed: 26085680
Transl Res. 2016 Jan;167(1):167-82
pubmed: 26207886
Br J Clin Pharmacol. 2015 Dec;80(6):1350-61
pubmed: 26261033
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11001-6
pubmed: 26283380
Arthritis Rheumatol. 2015 Dec;67(12):3146-57
pubmed: 26315890
Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15136-41
pubmed: 26598674
Annu Rev Pharmacol Toxicol. 2016;56:103-22
pubmed: 26738473
Bioorg Med Chem Lett. 2016 Feb 1;26(3):707-713
pubmed: 26764190
Sci Rep. 2016 Mar 09;6:22401
pubmed: 26956729
PLoS One. 2016 Apr 06;11(4):e0151999
pubmed: 27050551
Immunity. 2016 Aug 16;45(2):319-32
pubmed: 27521268
Cell Rep. 2016 Aug 30;16(9):2442-55
pubmed: 27545875
Mucosal Immunol. 2017 May;10(3):716-726
pubmed: 27759022
Nature. 2016 Nov 15;539(7630):479
pubmed: 27882996
JCI Insight. 2016 Dec 8;1(20):e88689
pubmed: 27942586
Cancer Sci. 2017 May;108(5):831-837
pubmed: 28266780
Nat Commun. 2017 Apr 25;8:15013
pubmed: 28440293
Int J Mol Sci. 2017 May 11;18(5):null
pubmed: 28492513
Circulation. 2017 Sep 19;136(12):1140-1154
pubmed: 28698173
Biochem Biophys Res Commun. 2017 Oct 14;492(2):192-198
pubmed: 28818665
J Biol Chem. 2017 Nov 10;292(45):18689-18698
pubmed: 28924041
Mol Cell Biol. 2018 Jan 16;38(3):null
pubmed: 29339435
Clin Exp Rheumatol. 2018 May-Jun;36(3):376-381
pubmed: 29352853
J Immunol. 1999 Feb 1;162(3):1496-501
pubmed: 9973406